MERIL Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT, Presented at EuroPCR 2024 - Earns Prestigious Late Breaking Trial Status & The LANCET Acceptance

Meril Life Sciences Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/meril-announces-successful-primary-outcomes-of-next-gen-myval-thv-series-in-major-rct-presented-at-europcr-2024---earns-prestigious-late-breaking-trial-status--the-lancet-acceptance-302145200.html